The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Alexion Pharmaceuticals Inc.’s new CEO Ludwig Hantson will need to refocus the rare disease specialist onto a steady growth track after the company's recent missteps. Alexion announced the appointment of Hantson, formerly Baxalta Inc.'s CEO, on March 27.
Hantson succeeds David Brennan, who stepped in on an interim basis in December after former CEO David Hallal resigned for...
Create an account to read this article
Already a subscriber?
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
The US FDA approved Insmed’s second product, the DPP1 inhibitor Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis. The company launched the drug immediately with a list price of $88,000 per year.
